March 23, 2017 (Shareholders Foundation) - An investigation on behalf of investors of Trevena Inc (NASDAQ:TRVN) shares over potential securities laws violations by Trevena Inc and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Trevena Inc (NASDAQ:TRVN) concerning whether a series of statements by Trevena Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

King of Prussia, PA based Trevena Inc. is a clinical-stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors.

February 21, 2017, Trevena Inc announced the clinical trial results for its morphine-alternative drug, Oliceridine, which revealed that the drug did not have statistically significant rates of higher tolerability or safety as compared to standard morphine.